Patrick Branigan, BS

Johnson & Johnson

Poster(s):

• P1082 - Impact of Subcutaneous Guselkumab Induction Therapy on Molecular Inflammation in Patients With Ulcerative Colitis: Results From the Phase 3 ASTRO Study
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM PDT

• P1120 - Comparison of Serum IL-22 and Tissue Molecular Changes Between Guselkumab Subcutaneous and Intravenous Induction in Moderately to Severely Active Crohn’s Disease: Post Hoc Analysis of the GRAVITI and GALAXI Studies
  Sunday, October 26, 2025

  3:30 PM - 7:00 PM PDT

• P5445 - Molecular Differentiation of Guselkumab and Ustekinumab in Moderately to Severely Active Crohn’s Disease: Post Hoc Analysis of the GALAXI 2 and 3 Phase 3 Studies
  Tuesday, October 28, 2025

  10:30 AM - 4:00 PM PDT